Existing therapies rely on drops or injections to deliver medicine, and often do not reach the retina or the inside of cells. iVeena uses novel approaches — including drug delivery from the lens capsule, minimally invasive implants, and intracellular therapy — to reach target tissues for better patient outcomes.


iVeena has nine products in late pre-clinical and research phase. Targeted indications include Post Surgery Cataract Inflammation, Macular Degeneration (Wet AMD), Diabetic Retinopathy, Glaucoma, and three orphan drug candidates.

Home page graphic update 100815

Back to top